Irrfan Khan, fight against cancer, returns to India



[ad_1]

Irrfan Khan was diagnosed with neuroendocrine tumor in March (courtesy image: Instagram)

New Delhi:

Actor Irrfan Khan, who was undergoing medical treatment in London, is returned to India, IANS news agency reports. He flew to London last March, after which he tweeted that he had been diagnosed with a rare form of cancer. Recently, several unconfirmed reports have also stated that once back in India, Irrfan Khan, 51, would start firing for the follow-up of Hindi Medium and that he would be groomed in a hospital in Mumbai. A source told IANS, "Irrfan is back in Mumbai, but people are publishing all kinds of stories without any confirmation." That's not true, "adding that Hindi Medium 2 was definitely on the cards, "But I do not know when the shoot will begin."

pic.twitter.com/JXD8NKwH3D

– Irrfan (@irrfank) March 5, 2018

.twitter.com/IDThvTr6yF

– Irrfan (@irrfank) March 16 2018

"I will be informed of his state of health and when he will resume work when I soon meet the actor" The source also told IANS.

The 2017 film by Irrfan Khan Hindi Medium which also featured Pakistani actress Saba Qamar, was hailed by critics. Dinesh Vijan, the producer, told IANS: "I will make an official announcement about the film in 15 days."

While in London, Irrfan Khan repeatedly shared health updates on Twitter. In an interview with Hindustan Times, he also explained his experience with chemotherapy sessions.

In November, it was widely reported that Irrfan Khan could return to India with his family for Diwali but would not shoot for movies.

On the labor front, besides Hindi Medium 2 a biographical film about Udham Singh, which will be directed by Shoojit Sircar, is Irrfan Khan's current project. His film with Deepika Padukone, directed by Vishal Bhardwaj, has been postponed indefinitely. During this time, he chose not to participate in the web series of Amazon Gormint . Karwaan is his latest release for Bollywood, which was screened during his stay in London.

(With IANS entries)

[ad_2]
Source link